Sepracor says it's staying put

Marlborough, MA-based Sepracor was quick to reassure the Boston biotech community that Dainippon's $2.6 billion acquisition of the company wouldn't interfere with its local operations. The Japanese company is widely viewed as most interested in Sepracor's sales platform as a launch point for new products. Analysts, meanwhile, have been offering some varying opinions as to whether another bidder for the company might suddenly appear. Report

Suggested Articles

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me

Q32 Bio is working on treatments for autoimmune and inflammatory diseases that improve on systemic approaches.